Patents by Inventor Elaine I. Tuomanen
Elaine I. Tuomanen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11207396Abstract: In some aspects, provided herein are methods and compositions for treating or preventing adverse cardiac events in a patient who has suffered an invasive pneumococcal infection or is at risk of such an infection. The compositions include fusion proteins comprising a CbpA polypeptide or active fragment or variant thereof and optionally a T cell epitope (TCE) and a third immunogenic polypeptide from a bacteria.Type: GrantFiled: May 19, 2014Date of Patent: December 28, 2021Assignees: The Board Of Regents Of The University Of Texas System, St. Jude Children's Research HospitalInventors: Carlos J. Orihuela, Elaine I. Tuomanen, Armand O. Brown
-
Publication number: 20160101172Abstract: In some aspects, provided herein are methods and compositions for treating or preventing adverse cardiac events in a patient who has suffered an invasive pneumococcal infection or is at risk of such an infection. The compositions include fusion proteins comprising a CbpA polypeptide or active fragment or variant thereof and optionally a T cell epitope (TCE) and a third immunogenic polypeptide from a bacteria.Type: ApplicationFiled: May 19, 2014Publication date: April 14, 2016Inventors: Carlos J. ORIHUELA, Elaine I. TUOMANEN, Armand O. BROWN
-
Patent number: 9265819Abstract: The present invention is an attenuated mutant strain of Streptococcus pneumonia that has a mutation in the FtsY gene. Vaccines, kits and methods for protecting a subject against Streptococcus pneumonia disease or colonization using the attenuated mutant strain are also provided.Type: GrantFiled: September 19, 2012Date of Patent: February 23, 2016Assignee: St. Jude Children's Research HospitalInventors: Jason W. Rosch, Elaine I. Tuomanen, Jonathan A. McCullers
-
Publication number: 20140314812Abstract: The present invention is an attenuated mutant strain of Streptococcus pneumonia that has a mutation in the FtsY gene. Vaccines, kits and methods for protecting a subject against Streptococcus pneumonia disease or colonization using the attenuated mutant strain are also provided.Type: ApplicationFiled: September 19, 2012Publication date: October 23, 2014Inventors: Jason W. Rosch, Elaine I. Tuomanen, Jonathan A. McCullers
-
Patent number: 7479282Abstract: This invention provides an isolated polypeptide comprising an amino acid sequence of a N-terminal choline binding protein A truncate in which the amino acid sequence is set forth in any of SEQ ID NOS: 1, 3-7, or 9-11, including fragments, mutants, variants, analogs, or derivatives, thereof. Also, this invention provides a isolated polypeptide comprising an amino acid sequence of a N-terminal choline binding protein A truncate, wherein the amino acid is set forth in SEQ ID NO: 24, wherein the polypeptide retains its native tertiary structure and methods of preparation. This invention provides an isolated polypeptide comprising an amino acid sequence of a N-terminal choline binding protein A truncate, wherein the polypeptide has lectin activity and does not bind to choline. This invention provides an isolated immunogenic polypeptide comprising an amino acid sequence of a N-terminal choline binding protein A truncate.Type: GrantFiled: January 5, 2004Date of Patent: January 20, 2009Assignees: St. Jude Children's Research Hospital, MedimmuneInventors: Elaine I. Tuomanen, Theresa M. Wizemann, H. Robert Masure, Leslie S. Johnson, Scott Koenig
-
Patent number: 6858706Abstract: This invention provides an isolated polypeptide comprising an amino acid sequence of a N-terminal choline binding protein A truncate in which the amino acid sequence is set forth in any of SEQ ID NOS: 1, 3-7, or 9-11, including fragments, mutants, variants, analogs, or derivatives, thereof. Also, this invention provides a isolated polypeptide comprising an amino acid sequence of a N-terminal choline binding protein A truncate, wherein the amino acid is set forth in SEQ ID NO 24, wherein the polypeptide retains its native tertiary structure and methods of preparation. This invention provides an isolated polypeptide comprising an amino acid sequence of a N-terminal choline binding protein A truncate, wherein the polypeptide has lectin activity and does not bind to choline. This invention provides an isolated immunogenic polypeptide comprising an amino acid sequence of a N-terminal choline binding protein A truncate.Type: GrantFiled: April 7, 1998Date of Patent: February 22, 2005Assignees: St. Jude Children's Research Hospital, MedImmune, Inc.Inventors: Elaine I. Tuomanen, Theresa M. Wizemann, H. Robert Masure, Leslie Sydnor Johnson, Scott Koenig
-
Publication number: 20040120966Abstract: This invention provides an isolated polypeptide comprising an amino acid sequence of a N-terminal choline binding protein A truncate in which the amino acid sequence is set forth in any of SEQ ID NOS: 1, 3-7, or 9-11, including fragments, mutants, variants, analogs, or derivatives, thereof. Also, this invention provides a isolated polypeptide comprising an amino acid sequence of a N-terminal choline binding protein A truncate, wherein the amino acid is set forth in SEQ ID NO: 24, wherein the polypeptide retains its native tertiary structure and methods of preparation. This invention provides an isolated polypeptide comprising an amino acid sequence of a N-terminal choline binding protein A truncate, wherein the polypeptide has lectin activity and does not bind to choline. This invention provides an isolated immunogenic polypeptide comprising an amino acid sequence of a N-terminal choline binding protein A truncate.Type: ApplicationFiled: January 5, 2004Publication date: June 24, 2004Applicants: St. Jude Children's Research Hospital, Medimmune, Inc.Inventors: Elaine I. Tuomanen, Theresa M. Wizemann, H. Robert Masure, Leslie Sydnor Johnson, Scott Koenig
-
Patent number: 6630583Abstract: The present invention discloses novel antibiotic peptides, including naturally occurring peptides. The present invention also includes the nucleic acid sequences encoding such peptides and the corresponding amino acid sequences. Methods of identifying, making, and using the antibiotic peptides are also disclosed. The present invention further provides novel proteins involved in the regulation of bacterial autolysis.Type: GrantFiled: January 28, 2000Date of Patent: October 7, 2003Assignee: St. Jude Children's Research HospitalInventors: Rodger Novak, Elaine I. Tuomanen
-
Patent number: 6623931Abstract: Allelic variation in the vex2, pep27 and vncS genes of bacteria responsible for tolerance to antibiotics such as penicillin and vancomycin, is taught. Methods for identifying antibiotic tolerant bacteria and subjects infected with such bacteria, particularly antibiotic tolerant Streptococcus pneumoniae, are provided. Test kits and components useful for performing such methods, particularly including oligonucleotide primers, are also provided.Type: GrantFiled: November 13, 2001Date of Patent: September 23, 2003Assignee: St. Jude Children's Research HospitalInventors: Robyn M. Atkinson, Elaine I. Tuomanen
-
Publication number: 20030175796Abstract: Allelic variation in the vex2, pep27 and vncS genes of bacteria responsible for tolerance to antibiotics such as penicillin and vancomycin, is taught. Methods for identifying antibiotic tolerant bacteria and subjects infected with such bacteria, particularly antibiotic tolerant Streptococcus pneumoniae, are provided. Test kits and components useful for performing such methods, particularly including oligonucleotide primers, are also provided.Type: ApplicationFiled: May 2, 2003Publication date: September 18, 2003Applicant: St. Jude Children's Research Hospital, Inc.Inventors: Robyn M. Atkinson, Elaine I. Tuomanen
-
Publication number: 20030113343Abstract: The present invention provides isolated polypeptides comprising an amino acid sequence of a choline binding protein CbpG. This invention provides an isolated polypeptide comprising an amino acid sequence of a choline binding polypeptide CbpG or N-terminal CbpG truncate, including analogs, variants, mutants, derivatives and fragments thereof. This invention further provides an isolated immunogenic polypeptide comprising an amino acid sequence of a choline binding protein CbpG. This invention provides an isolated nucleic acid encoding a polypeptide comprising an amino acid sequence of a choline binding protein CbpG. This invention provides pharmaceutical compositions, vaccines, and diagnostic and therapeutic methods of use of the isolated polypeptides and nucleic acids. Assays for compounds which alter or inactivate the polypeptides of the present invention for use in therapy are also provided.Type: ApplicationFiled: September 13, 2002Publication date: June 19, 2003Applicant: St. Jude Children's Research HospitalInventors: Elaine I. Tuomanen, Khoosheh Gosink, Robert Masure
-
Publication number: 20030096950Abstract: This invention provides an isolated polypeptide comprising an amino acid sequence of a N-terminal choline binding protein A truncate in which the amino acid sequence is set forth in any of SEQ ID NOS: 1, 3-7, or 9-11, including fragments, mutants, variants, analogs, or derivatives, thereof.Type: ApplicationFiled: April 7, 1998Publication date: May 22, 2003Inventors: ELAINE I. TUOMANEN, THERESA M WIZEMANN, H. ROBERT MASURE, LESLIE SYDNOR JOHNSON, SCOTT KOENIG
-
Patent number: 6495139Abstract: The present invention provides isolated polypeptides comprising an amino acid sequence of a choline binding protein CbpG. This invention provides an isolated polypeptide comprising an amino acid sequence of a choline binding polypeptide CbpG or N-terminal CbpG truncate, including analogs, variants, mutants, derivatives and fragments thereof This invention further provides an isolated immunogenic polypeptide comprising an amino acid sequence of a choline binding protein CbpG. This invention provides an isolated nucleic acid encoding a polypeptide comprising an amino acid sequence of a choline binding protein CbpG. This invention provides pharmaceutical compositions, vaccines, and diagnostic and therapeutic methods of use of the isolated polypeptides and nucleic acids. Assays for compounds which alter or inactivate the polypeptides of the present invention for use in therapy are also provided.Type: GrantFiled: April 6, 1999Date of Patent: December 17, 2002Assignee: St. Jude Children's research HospitalInventors: Elaine I. Tuomanen, Khoosheh Gosink, Robert Masure
-
Publication number: 20020164623Abstract: Allelic variation in the vex2, pep27 and vncS genes of bacteria responsible for tolerance to antibiotics such as penicillin and vancomycin, is taught. Methods for identifying antibiotic tolerant bacteria and subjects infected with such bacteria, particularly antibiotic tolerant Streptococcus pneumoniae, are provided. Test kits and components useful for performing such methods, particularly including oligonucleotide primers, are also provided.Type: ApplicationFiled: November 13, 2001Publication date: November 7, 2002Applicant: St. Jude Children's Research Hospital, Inc.Inventors: Robyn M. Atkinson, Elaine I. Tuomanen
-
Patent number: 6448224Abstract: The present invention discloses novel antibiotic peptides, including naturally occurring peptides. The present invention also includes the nucleic acid sequence encoding such peptides and the corresponding amino acid sequences. Methods of identifying, making, and using the antibiotic peptides are also disclosed.Type: GrantFiled: May 6, 1998Date of Patent: September 10, 2002Assignee: St. Jude Children's Research HospitalInventors: Rodger Novak, Elaine I. Tuomanen
-
Publication number: 20020041881Abstract: The present invention provides isolated polypeptides comprising an amino acid sequence of a choline binding protein CbpG. This invention provides an isolated polypeptide comprising an amino acid sequence of a choline binding polypeptide CbpG or N-terminal CbpG truncate, including analogs, variants, mutants, derivatives and fragments thereof. This invention further provides an isolated immunogenic polypeptide comprising an amino acid sequence of a choline binding protein CbpG. This invention provides an isolated nucleic acid encoding a polypeptide comprising an amino acid sequence of a choline binding protein CbpG. This invention provides pharmaceutical compositions, vaccines, and diagnostic and therapeutic methods of use of the isolated polypeptides and nucleic acids. Assays for compounds which alter or inactivate the polypeptides of the present invention for use in therapy are also provided.Type: ApplicationFiled: April 6, 1999Publication date: April 11, 2002Inventors: ELAINE I. TUOMANEN, KHOOSHEH GOSINK, ROBERT MASURE
-
Patent number: 6331407Abstract: The present invention discloses novel antibiotic peptides, including naturally occurring peptides. The present invention also includes the nucleic acid sequences encoding such peptides and the corresponding amino acid sequences. Methods of identifying, making, and using the antibiotic peptides are also disclosed. The present invention further provides novel proteins involved in the regulation of bacterial autolysis.Type: GrantFiled: May 5, 1999Date of Patent: December 18, 2001Assignee: St. Jude Children's Research HospitalInventors: Rodger Novak, Elaine I. Tuomanen
-
Patent number: 5665561Abstract: The present invention relates to compositions and methods for preventing pneumococcal infection. In particular, this invention relates to the identification of the minimum receptor targets of pneumococcal adherence to pulmonary and vascular endothelium, and to compositions and methods for preventing such adherence. In particular, the invention relates to the ability of one or more carbohydrate entities having the following motif or motifs: a disaccharide N-acetyl-D-galactosamine .beta.1-3Gal motif, a disaccharide N-acetyl-D-galactosamine .beta.1-4Gal motif, and an N-acetyl-D-glucosamine motif, effective to induce elution of adherent S. pneumoniae from host cells. In particular, a composition containing all three motifs can elute about 100% of pneumococcal bacteria from lung epithelial cells, and from venous endothelial cells. In a particular embodiment, a pharmaceutical composition of the invention can be used to treat pneumococcal infections in which the host cells are lung epithelial cells.Type: GrantFiled: June 6, 1994Date of Patent: September 9, 1997Assignee: The Rockefeller UniversityInventors: Elaine I. Tuomanen, Diana R. Cundell
-
Patent number: 5455240Abstract: The present invention relates to compositions and methods for preventing pneumococcal infection. In particular, the invention relates to identification of the major reception for Streptococcus pneumoniae on activated human cells, and diagnostic and therapeutic compositions and methods based thereon. In particular, the invention relates to the discovery that platelet activating factor (PAF) receptor is an adhesive ligand for pneumococcal adherence to activated lung epithelial and venous endothelial (i.e., host) cells. Accordingly, the present invention is directed to a method for preventing or treating an infection with Streptococcus pneumoniae by administering an antagonist of platelet activating factor receptor. The invention further relates to recognition that adherence to activated cells also involves a carbohydrate ligand found on such activated cells.Type: GrantFiled: June 20, 1994Date of Patent: October 3, 1995Assignees: The Rockefeller University, Beth Israel Hospital AssociationInventors: Elaine I. Tuomanen, Diana R. Cundell, Norma P. Gerard